The PPAR-γ agonists thiazolidinediones (TZDs) have a hypoglycemic action in ob/ob mice and improve insulin action in several models of obesity and diabetes [47,48]. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.